Novavax (NVAX) Projected to Post Quarterly Earnings on Friday

Novavax (NASDAQ:NVAX - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Friday, May 9th. Analysts expect the company to announce earnings of $0.19 per share and revenue of $204.08 million for the quarter.

Novavax (NASDAQ:NVAX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating analysts' consensus estimates of ($0.75) by $0.24. The business had revenue of $88.31 million for the quarter, compared to the consensus estimate of $85.48 million. During the same period in the previous year, the company earned ($1.44) EPS. On average, analysts expect Novavax to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Novavax Stock Performance

NVAX stock remained flat at $6.41 on Friday. The company had a trading volume of 3,628,219 shares, compared to its average volume of 8,383,053. The company has a 50-day moving average price of $7.01 and a two-hundred day moving average price of $8.16. The stock has a market capitalization of $1.03 billion, a price-to-earnings ratio of -2.84, a PEG ratio of 2.85 and a beta of 3.15. Novavax has a 12 month low of $4.43 and a 12 month high of $23.86.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. BTIG Research initiated coverage on shares of Novavax in a research note on Friday, February 28th. They set a "buy" rating and a $19.00 target price on the stock. TD Cowen raised shares of Novavax to a "hold" rating in a research report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $18.00.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.